Follistatin-like protein-1 as a biomarker for inflammatory disorders
First Claim
1. A method of diagnosing an inflammatory disorder in a human patient comprising:
- (a) measuring the level of human FSTL-1 in a sample collected from the patient suspecting having an inflammatory disorder by an enzyme-linked immunosorbent assay; and
(b) diagnosing that the patient has an inflammatory disorder if the level of human FSTL-1 in the sample of the patient is measured to be between about 200 and 300 ng/ml, andwherein the inflammatory disorder is systemic onset juvenile idiopathic arthritis or Kawasaki disease.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods and compositions for diagnosis of inflammatory disorders, and in non-limiting embodiments, of inflammatory disorders associated with elevated interleukin-1β (“IL-1β”), based on increased levels of follistatin-like protein 1 (“FSTL-1”). In particular non-limiting embodiments, the invention further provides for methods of identifying subjects with systemic onset juvenile idiopathic arthritis (“SOJIA”) who are at increased risk for developing macrophage activation syndrome (“MAS”) comprising detecting, in said subjects, hyper-increased levels of FSTL-1. In additional non-limiting embodiments, the invention provides for methods of identifying subjects with Kawasaki disease who are at increased risk of developing aortic aneurysms comprising detecting, in said subjects, hyper-increased levels of FSTL-1.
-
Citations
11 Claims
-
1. A method of diagnosing an inflammatory disorder in a human patient comprising:
-
(a) measuring the level of human FSTL-1 in a sample collected from the patient suspecting having an inflammatory disorder by an enzyme-linked immunosorbent assay; and (b) diagnosing that the patient has an inflammatory disorder if the level of human FSTL-1 in the sample of the patient is measured to be between about 200 and 300 ng/ml, and wherein the inflammatory disorder is systemic onset juvenile idiopathic arthritis or Kawasaki disease. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method of identifying a patient with systemic onset juvenile idiopathic arthritis who is at increased risk for developing macrophage activation syndrome comprising:
-
(a) measuring the level of human FSTL-1 in a sample collected from the patient by an enzyme-linked immunosorbent assay; and (b) identifying the patient with systemic onset juvenile idiopathic arthritis as being at increased risk for developing macrophage activation syndrome if the level of human FSTL-1 in the sample of the patient is measured to be increased by about 40 percent or more relative to control levels. - View Dependent Claims (7, 8)
-
-
9. A method of identifying a patient with Kawasaki disease who is at increased risk for developing macrophage activation syndrome comprising:
-
a) measuring the level of human FSTL-1 in a sample collected from the patient by an enzyme-linked immunosorbent assay; and (b) identifying the patient with Kawasaki disease as being at increased risk for developing macrophage activation syndrome if the level of human FSTL-1 in the sample of the patient is measured to be increased by about 50 percent or more relative to control levels. - View Dependent Claims (10, 11)
-
Specification